Pacira Pharmaceuticals (PCRX) Stock Statistics & Valuation Metrics

Pacira Pharmaceuticals has a market cap or net worth of $941.79M. The enterprise value is $1.30B.

Pacira Pharmaceuticals has 40,489,895 shares outstanding. The number of shares has decreased by -2.65% in one year.

Pacira Pharmaceuticals’s return on equity (ROE) is 0.01 and return on invested capital (ROIC) is 1.02%.

The current PE Ratio of Pacira Pharmaceuticals is 164.0. Pacira Pharmaceuticals’s PEG ratio is -1.53.

In the last 12 months, Pacira Pharmaceuticals had revenue of 726.41M and earned 7.03M in profits. Earnings per share was 0.16.

In the last 12 months, operating cash flow was 151.99M and capital expenditures -15.33M, giving a free cash flow of 136.66M billion.

Pacira Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Pacira Pharmaceuticals upcoming earnings date is May 6, 2026, Before Open (Confirmed).

Pacira Pharmaceuticals as a current ratio of 4.54, with Debt / Equity ratio of 65.56%

In the past 12 months, Pacira Pharmaceuticals has paid 9.84M in taxes.

Pacira Pharmaceuticals EV to EBITDA ratio is 12.17, with an EV/FCF ratio of 10.60.

Pacira Pharmaceuticals has $238.42M in cash and marketable securities with $454.38M in debt, giving a net cash position of -$215.96M billion.

Gross margin is 77.41%, with operating margin of 3.87%, and net profit margin of 0.97%.

The average price target for Pacira Pharmaceuticals is $30.60, which is 11.43% higher than the current price. The consensus rating is Strong Buy